[Comment] Growing evidence supports 4CMenB effectiveness

Meningococcal disease remains one of the most feared infectious diseases globally because of its sudden onset, rapid progression, high case fatality rate, and severe neurodevelopmental sequelae among survivors. Of the 12 known meningococcal capsular groups, group B (MenB) is responsible for most cases of invasive disease in Europe, especially in young children.1 Unlike the highly effective polysaccharide-conjugate vaccines against groups A, C, W, and Y, the development of a similar vaccine for MenB has been challenging because the capsular polysaccharide of MenB is structurally similar to fetal neural cell adhesion molecules.

Source: The Lancet Infectious Diseases - January 19, 2018 Category: Infectious Diseases Authors: Shamez N Ladhani, Ray Borrow, Nick J Andrews Tags: Comment Source Type: research